Buscar resultados de ensayos clínicos
Neurofibromatosis Type 2 - 25 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Condición:
Fecha: 2016-10-13 Intervenciones: Drug: Icotinib Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Tot |
Completed |
Nombre del estudio: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Condición:
Fecha: 2014-03-26 Intervenciones: Drug: Endostatin Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Cours |
Recruiting |
Nombre del estudio: Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Condición:
Fecha: 2014-04-29 Intervenciones: Drug: Axitinib Other Name: Inlyta |
Completed |
Nombre del estudio: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Condición: Neurofibromatosis Type II Fecha: 2011-08-17 Intervenciones: Drug: Everolimus (RAD001) , Afinitor® Everolimus will be provided by Novartis. Everolimus is formul |
Suspended |
Nombre del estudio: PTC299 for Treatment of Neurofibromatosis Type 2 Condición: Neurofibromatosis 2 Fecha: 2009-05-28 Intervenciones: Drug: PTC299 PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until t |
Recruiting |
Nombre del estudio: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Condición:
Fecha: 2011-04-21 Intervenciones: Drug: RAD001, everolimus Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily |
Completed |
Nombre del estudio: Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Condición:
Fecha: 2010-09-01 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Condición:
Intervenciones: Drug: Bevacizumab Treatment will be administered on an out |
No longer available |
Nombre del estudio: Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients Condición:
|
Completed |
Nombre del estudio: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Condición: Neurofibromatosis 2 Fecha: 2011-11-30 Intervenciones: Drug: RAD001 10 mg per os / day or 05mg per os / day with 12 month |